By: Melanie Cerullo

INTRODUCTION

As drug development portfolios expand across multiple delivery platforms, increasing complexity places quality systems under greater strain. For contract development and manufacturing organizations (CDMOs) supporting injectable, inhalation, nasal and transdermal products in parallel, the quality management system (QMS) must do more than ensure compliance. It must provide a coherent framework for decision-making, while maintaining control and enabling scientifically sound, phase-appropriate flexibility.

From my perspective, the differentiator is a quality system that manages risk consistently across platforms. A harmonized QMS, supported by clear governance and strong site-level execution, is essential to de-risk development, accelerate progress and sustain regulatory confidence.

MANAGING A DIVERSIFIED PORTFOLIO WITHOUT FRAGMENTING QUALITY

Modern development pipelines increasingly include complex formulations, combination products and advanced delivery systems, each with distinct critical quality attributes and failure modes. When these products are managed within siloed or platform-specific quality systems, inconsistency becomes inevitable.

Injectable products demand absolute control of sterility, particulates and endotoxins. These expectations are well understood, but complexity increases with long-acting injectables, high-viscosity formulations or turbid products that challenge conventional sterility and particulate testing approaches. Without a disciplined quality framework, method variability and inconsistent risk justification quickly emerge.

Pulmonary and nasal products are drug–device combination products that require coordinated control of formulation, device performance, extractables and leachables, and patient use considerations. For inhalation and nasal delivery, aerodynamic particle size distribution is a critical quality attribute that directly affects dose delivery, placing significant demands on validated, reproducible analytical methods.

Transdermal products present equally demanding challenges that require robust control of formulation stability, uniformity, adhesion and controlled release. Risks such as active substance crystallization, process residue carryover or solvent retention can directly affect performance and patient safety. In practice, these risks often justify controls that go beyond minimum compendial or guideline expectations.

Across all platforms, regulatory expectations are consistent in one respect: quality must be designed into the product and demonstrated through data. A fragmented quality approach cannot reliably meet this standard.

WHY A HARMONIZED QMS IS ESSENTIAL

A unified pharmaceutical quality system provides the backbone for managing complexity by defining how quality decisions are made, documented, reviewed and improved.

Across platforms and sites, deviation management, corrective and preventive action (CAPA), change control, supplier qualification and management review should follow one set of expectations and one workflow. This consistency supports inspection readiness and gives leadership an enterprise-level view of performance and risk, consistent with International Council for Harmonisation (ICH) Q10.

CAPA and change control warrant particular focus because they link day-to-day execution to systemic improvement. When these processes vary by site, issues recur, root cause analysis loses rigor and lessons stay local rather than strengthening the network.

EMBEDDING FLEXIBILITY THROUGH QUALITY RISK MANAGEMENT

While management systems must be standardized, technical execution must remain risk-based. This is where quality risk management, aligned with ICH Q9, becomes essential.

A mature QMS embeds risk management into everyday decision-making. Tools such as failure modes and effects analysis (FMEA) are not treated as one-time exercises, but as living assessments that inform method development, validation strategies, process changes and control selection.

This approach supports phase-appropriate analytical strategies, with early clinical programs relying on fit-for-purpose methods that enable speed and learning. As products advance, validation rigor increases in line with patient exposure and regulatory expectations. The QMS defines the framework and governance for these decisions, while risk assessments justify the technical path forward.

This balance between structure and flexibility is where many quality systems fail. Either they over-standardize, slowing development unnecessarily, or they allow excessive local discretion without sufficient governance. Neither of these models is sustainable at scale.

EXECUTION FUNDAMENTALS: DATA INTEGRITY & DEFINED ACCOUNTABILITY

Even the best-designed QMS fails without disciplined execution. Two elements are particularly critical: data integrity and clear accountability between sponsor and CDMO.

A harmonized QMS must enforce consistent computer system validation, access control, audit trails and record retention across all platforms and sites to protect the data integrity that is fundamental to every quality decision. Alignment with global regulatory expectations, including Title 21 of the Code of Federal Regulations Part 11 and ALCOA+ (attributable, legible, contemporaneous, original, accurate, plus complete, consistent, enduring and available) principles, is essential. Without confidence in data, neither sponsors nor regulators can rely on the product.

Equally important are well-defined quality agreements. Sponsors retain ultimate responsibility for product quality, regardless of outsourcing. These agreements must clearly define roles, responsibilities, escalation pathways and decision rights, with appropriate recognition of platform-specific risks. Ambiguity in this area is a common root cause of compliance failures.

GOVERNANCE THAT ENABLES CONSISTENCY & EXPERTISE

A governance model that combines centralized quality oversight with strong, empowered site-level expertise maintains consistency while enabling platform-specific execution.

Central quality functions set standards and ensure regulatory alignment, while site teams execute scientifically and manage platform-specific risk. This balance avoids the pitfalls of over-centralization, which can suppress technical judgment, and over-decentralization, which leads to inconsistency.

This model is particularly important for deviations, CAPA and change control, where common definitions and workflows support consistent execution and comparable performance metrics. When governance is clear, decisions are faster, more consistent and more defensible.

QUALITY SYSTEMS THAT SCALE WITH COMPLEXITY

As development portfolios diversify and technical complexity increases, quality systems must evolve accordingly. A QMS that is siloed, overly localized or inconsistently applied will not withstand regulatory scrutiny or support reliable execution at scale.

A coordinated, risk-based quality system with clear governance provides the foundation for managing multiple delivery platforms without compromising control. When core processes are standardized and risk management is embedded, quality becomes predictable and defensible. Enabling site expertise within defined boundaries makes that performance sustainable.

For sponsors, the expectation should be clear: a CDMO’s quality system must do more than meet baseline compliance. It must demonstrate how risk is identified and reduced across the product lifecycle. For CDMOs, this requires disciplined execution, with oversight that drives continuous improvement.

When quality systems are designed to manage complexity rather than react to it, they enable faster development, stronger regulatory outcomes, and, ultimately, consistent delivery of safe and effective medicines to patients.

BIOGRAPHY